A2780 Cell Line human

93112519, human ovary, Epithelial

• Sinónimos: A-2780 Cells
• UNSPSC Code: 41106514

Propiedades

• product name: A2780 Cell Line human, ovarian carcinoma, 93112519
• biological source: human ovary
• growth mode: Adherent
• karyotype: Not specified
• morphology: Epithelial
• products: Not specified
• receptors: Not specified
• technique(s): cell culture | mammalian: suitable
• relevant disease(s): cancer
• shipped in: dry ice
• storage temp.: −196°C

Descripción

Cell Line Origin

Human ovarian carcinoma

Cell Line Description

The A2780 human ovarian cancer cell line was established from tumour tissue from an untreated patient. Cells grow as a monolayer and in suspension in spinner cultures. A2780 is the parent line to the cisplatin resistant cell line A2780 cis (Sigma catalogue no. 93112517) and the adriamycin resistant cell line A2780 ADR (Sigma catalogue no. 93112520).

Application

A2780 cell line human is used in toxicity testing and cancer genetic studies.
A2780 cell line human has been used to:

• study the role of Snail and Slug in ovarian tumor neovascularization
• overcome cisplatin resistance in ovarian cancer cells using liposome application
• demonstrate the significance of NMDA (N-methyl-D-aspartate) receptors as targets for treatment of ovarian cancers
• study the effect of low molecular weight heparin tinzaparin on cisplatin resistance in ovarian cancer cells

DNA Profile

STR-PCR Data: Amelogenin: X
CSF1PO: 10,11
D13S317: 12,13
D16S539: 11,13
D5S818: 11,12
D7S820: 10
THO1: 6
TPOX: 8,10
vWA: 15,16

Culture Medium

RPMI-1640 + 2mM Glutamine + 10% Foetal Boving Serum (FBS).

Subculture Routine

Split sub-confluent cultures (70-80%) 1:3 to 1:6 i.e. seeding at 3-6x10,000cells/cm² using 0.05% Trypsin or Trypsin/EDTA; 5% CO₂; 37°C.

Other Notes

Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.

Disclaimer

This cell line has special release conditions: Commercial organisations are required to complete the ′Cell Line Release Authorisation for Research Use in Commercial Organisations′ release conditions form.